MV-010

Indicaton

MV-010 is an orally available recombinant bacterial enzyme formulated by an exclusively licensed platform to restore intestinal immune system homeostasis in inflammatory bowel disease (IBD).

Therapeutic indications

Inflammation

Type of product

Other biologics

Table

Phase

Discovery
Partnering status

Not partnered

You may also be interested in

Breast cancer screening test

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening. The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases. Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Phase II completed

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

AUP-16 (AUP1602-C)

AUP-16 is a multi-therapy live bacterial vector for chronic wounds: Diabetic Foot, Leg & Pressure Ulcers

Phase II started